Bausch + Lomb (BLCO)

Healthcare · Medical Instruments & Supplies
$17.21 +0.17% on the day Market cap $6.1B 52-week range $13.77 to $18.92 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Bausch + Lomb's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

D

Five factors scored 1 to 9 from BLCO's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation8
Profitability1
Growth5
Financial health4
Cash efficiency0

Key numbers

P/E (trailing)—
P/E (forward)15.7x
Price / free cash flow—
EV / EBITDA14.8x
Price / sales1.14x
Price / book0.96x
Revenue growth+9.1%
Operating margin6.1%
Net margin-3.2%
Return on equity-2.7%
Dividend yield—
Debt / equity1.16x

Results from SEC filings

Fiscal years, from Bausch + Lomb's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$3.8B$3.8B$4.1B$4.8B$5.1B
Net income$182M$6M-$260M-$317M-$360M
Free cash flow$680M$170M-$198M-$59M-$66M
EPS (diluted)$0.52$0.02-$0.74-$0.90-$1.02
Operating margin8.7%5.5%3.1%3.4%2.2%

Where the revenue comes from

Revenue by segments, fiscal 2025.

Vision Care$2.9B57%
Pharmaceuticals$1.3B25%
Surgical$894M18%

Superinvestors who own BLCO

From each investor's latest 13F filing (what a 13F shows).

None of the superinvestors we track held BLCO in their latest 13F.

Insider buying

Open-market purchases by Bausch + Lomb's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Mar 6, 2026 A Robert D Bailey
14,600$17.15$250,390
Mar 6, 2026 Brent L Saunders
14,700$17.14$251,958
Mar 6, 2026 Sam Eldessouky
4,000$17.13$68,520

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when BLCO trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Bausch + Lomb insiders buying the stock?

3 open-market insider purchases of BLCO in the last 12 months, from SEC Form 4 filings.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.